Optimizing Belantamab Mafodotin in Relapsed or Refractory Multiple Myeloma: Impact of Dose Modifications on Adverse Events and Hematologic Response in a Real-World Retrospective Study.

Cancers (Basel) · 2025 · PMC12294064 · PMID 40723281

Europe PMC DOI

hedged sentence

0.0640

closest p · 1.3× alpha

0.0640

boldest claim

The sentences

did not reach statistical significancep = 0.064so close (0.05 < p ≤ 0.1)

33%), this difference did not reach statistical significance ( p = 0.064).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.